Skip to main content
🎯ONCOLOGY

Cancer

From blunt chemotherapy to SI-designed precision therapies: cancer is becoming a managed disease

~20 million new cases/year globally; ~10 million deaths/year: the second leading cause of death worldwide
CURE AVAILABLE
92/ 100
TO BROAD CURE

MILESTONEZiihera (zanidatamab-hrii) received FDA approval for first-line HER2+ advanced gastric/GEJ.

LATESTFDA expanded dostarlimab (Jemperli) accelerated approval for a locally advanced rectal subset.

An approved cure exists for a major form of this disease Β· Not medical advice.

CURRENT STATUS

Oncology has fractured from four blunt modalities (surgery, radiation, chemo, hormone therapy) into dozens of precision approaches. Six CAR-T products, multiple bispecifics, checkpoint inhibitors, antibody-drug conjugates and the first TIL therapy are all FDA-approved; individualized mRNA neoantigen vaccines and in-vivo CRISPR are in late- and early-phase trials respectively.

KEY BREAKTHROUGHS

Grail Galleri: multi-cancer early detection from a single blood draw, detecting 50+ cancer types

BioNTech/Moderna personalized mRNA cancer vaccines in Phase III for melanoma and pancreatic cancer

CRISPR-edited CAR-T cells (CTX110) achieving remissions without donor matching

AI-designed drug Recursion REC-4881 entering Phase II for familial adenomatous polyposis

SI-COMPRESSED PIPELINE

SI TOOLS ACCELERATING CURES

Multi-Cancer Early DetectionNeoantigen Prediction SICRISPR CAR-T EngineeringTumor Digital Twins

KEY ORGANIZATIONS

Grail (Illumina)BioNTechModernaCRISPR TherapeuticsRecursionFoundation Medicine

KEY CLINICAL TRIALS

INTerpath-001: mRNA-4157 (V940) + Keytruda in Melanoma (Phase 3)

View

Moderna / Merck

A personalized mRNA vaccine encoding up to 34 tumor-specific neoantigens, given with pembrolizumab after surgery for high-risk melanoma. Phase 2b data showed the combination cut recurrence-or-death risk by 49% versus pembrolizumab alone: now in global Phase 3 confirmation.

πŸ‘₯ ~1,089 participants with resected Stage IIB–IV melanomaπŸ“ Global: multicenter

Autogene Cevumeran (BNT122) in Pancreatic Cancer (Phase 2)

View

Genentech / BioNTech

An individualized mRNA neoantigen vaccine for resected pancreatic cancer, given with atezolizumab and chemotherapy. In Phase 1, vaccine-induced T cells persisted for years and delayed recurrence in responders: a first real signal against one of the deadliest cancers.

πŸ‘₯ ~260 participants with resected pancreatic ductal adenocarcinomaπŸ“ US, EU: multicenter

INTerpath-002: mRNA-4157 (V940) + Keytruda in Lung Cancer (Phase 3)

View

Moderna / Merck

Extends the personalized neoantigen vaccine approach to resected non-small cell lung cancer, testing whether adjuvant mRNA-4157 plus pembrolizumab prevents recurrence better than pembrolizumab alone.

πŸ‘₯ ~868 participants with resected Stage II–IIIB NSCLCπŸ“ Global: multicenter

TIMELINE ESTIMATE

Early detection (all cancers): 2–3 years to routine screening. Personalized vaccines: 3–5 years. Pan-cancer control: 10–15 years.

EXPLORE FULL CURE PROTOCOL